MedTrace Logo

ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa

NCT07783542 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2026-08-31

No results posted yet for this study

Summary

This is a multicenter, randomized, double-blinded, placebo-controlled clinical study of ORKA-002 in adult participants with moderate-to-severe HS.

Conditions

  • Hidradenitis Suppurativa (HS)

Interventions

DRUG

ORKA-002

ORKA-002 administered by subcutaneous (SC) injection

OTHER

Placebo

Placebo administered by subcutaneous (SC) injection

Sponsors & Collaborators

  • Oruka Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-20
Primary Completion
2028-10-31
Completion
2029-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07783542 on ClinicalTrials.gov